Seko et al. conducted a retrospective study that compared treatment between SGLT2 inhibitors and DPP-4 inhibitors in T2DM patients with biopsy proven NAFLD. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.